Nova Satra DX’ $72 Million Merger with INEX Innovations Exchange


K&L Gates advised Nova Satra DX Pte. Ltd. on the deal.

Nova Satra DX Pte. Ltd. concluded a merger with INEX Innovations Exchange Pte. Ltd.

The deal, valued at US$72 million, is backed by institutional investors including Genting, Enterprise Singapore, SEEDS Capital and SNS Holdings.

The transaction will result in the restructuring of the INEX group in which NSDX now becomes a part of INEX Innovate, one of Southeast Asia’s largest med-tech specialist companies in cancer research and development.

The combined company will be focused on addressing the unmet need for faster and more accurate diagnostics testing and precision health care for Asian women.

INEX Innovate is Asia’s first femtech innovations group, providing precision health care for women, specifically for Asian phenotypes. INEX Innovate has a broad commercial portfolio of validated tests in prenatal health, ovarian and breast cancer along with more than 45 key patents and nine trademarks worldwide.

Nova Satra Dx operates as a molecular diagnostics company. The Company researches, develops, and commercializes blood-based tests that provides detection of breast, colon, lung, prostate, and stomach cancers.

K&L Gates team was led by Singapore partners Nicholas Hanna (Picture) and Mark Tan, assisted by Singapore associates Lisa Hui and Mayumi Soh.

Involved fees earner: Nicholas Hanna – K&L Gates; Lisa Hui – K&L Gates; Mayumi Soh – K&L Gates; Mark Tan – K&L Gates;

Law Firms: K&L Gates;

Clients: Nova Satra DX Pte Ltd;